EcoDrugPlus

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSCJAG00000008874
Gene Symbol: ERBB2
5 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSCJAG00000011936
Gene Symbol: ERBB3
3 Cross references
280 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSCJAG00000011307
Gene Symbol: ERBB4
5 Cross references
320 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 1

Ensembl ID : ENSCJAG00000013293
Gene Symbol: ESR1
5 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 2

Ensembl ID : ENSCJAG00000019502
Gene Symbol: ESR2
4 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Related Receptor Gamma

Ensembl ID : ENSCJAG00000015141
Gene Symbol: ESRRG
5 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Exportin 1

Ensembl ID : ENSCJAG00000008877
Gene Symbol: XPO1
5 Cross references
296 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSCJAG00000003988
Gene Symbol: FDFT1
5 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSCJAG00000003507
Gene Symbol: FNTA
5 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSCJAG00000019689
Gene Symbol: FNTB
5 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fatty Acid Amide Hydrolase

Ensembl ID : ENSCJAG00000021138
Gene Symbol: FAAH
5 Cross references
131 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fibroblast Activation Protein Alpha

Ensembl ID : ENSCJAG00000005868
Gene Symbol: FAP
5 Cross references
127 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).